In­dus­try speaks out against ICER's sug­gest­ed up­dates to as­sess­ment frame­work

Drug­mak­ers and in­dus­try groups have crit­i­cized the In­sti­tute for Clin­i­cal and Eco­nom­ic Re­view af­ter the cost-ef­fec­tive­ness watch­dog said it may con­sid­er low­er­ing the thresh­old for how it con­sid­ers how cost-ef­fec­tive a drug is in the fu­ture.

ICER last month an­nounced pro­posed changes to the way the or­ga­ni­za­tion de­ter­mines the val­ue of a drug as part of a broad­er ex­am­i­na­tion of its val­ue as­sess­ment frame­work. It said it may low­er its thresh­old range on cost ef­fec­tive­ness to $50,000 to $100,000 a year, down from $100,000 to $150,000 a year, cit­ing a study pub­lished in the An­nals of In­ter­nal Med­i­cine in 2021.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER